Menu
ncarol.com
  • Home
  • Business
  • Real Estate
  • Health
  • Non-profit
  • Beauty
  • Services
  • Arts
  • Education
ncarol.com

National Brain Tumor Society to Launch Campaigns Elevating the Necessity of Clinical Trials and Biomarker Testing Access
ncarol.com/10235124

Trending...
  • "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
Joint initiatives aim to help patients and families navigate the era of precision medicine in cancer care

NEWTON, Mass. - ncarol.com -- National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, today announced the launch of two interrelated public health campaigns focused on patient awareness and access to advanced biomarker testing and clinical trials.

"While continued investment and concerted drug development efforts are certainly needed, the precision medicine era has arrived for patients with brain tumors," said David Arons, president and chief executive officer of NBTS. "With the World Health Organization's two recent reclassifications of central nervous system tumors in 2016 and 2021, patients with brain tumors need more precise diagnoses. These recent advances in the understanding of the molecular characteristics of tumor types, as well as new drug approvals and encouraging results from recent clinical trials, call for a greater understanding of patient options from the point of diagnosis. We want to ensure that brain tumors undergo comprehensive biomarker analysis and that patients and their care partners better understand and have improved access to clinical trials and expanded access options that might be their best source of care. To achieve this result, the NBTS campaigns will inform patients, seek improved coverage from insurers, and work with providers."

More on ncarol.com
  • Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology
  • Salena Kelley Returns as Ms. Salena With New Holiday Music Now Streaming Everywhere
  • UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
  • Burgerfi Set To Open New Restaurant In North Raleigh (wakefield), North Carolina This Winter
  • 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree

NBTS is launching the campaigns based on data on educational gaps in the brain tumor community gathered via a broad survey. Data collection analysis will inform future strategies, in addition to already planned educational and engagement activities.

The campaigns are being launched and developed with the generous support from Bayer, Danaher Foundation, and Servier Pharmaceuticals.

About the National Brain Tumor Society

Building on over 30 years of experience, the National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes, and unites the brain tumor community to discover a cure, deliver effective treatments, and advocate for patients and caregivers. Our focus on defeating brain tumors and improving the quality of patients' lives is powered by our partnerships across science, healthcare, policy, and business sectors. We fund treatments-focused research and convene those most critical to curing brain tumors once and for all. Join us at BrainTumor.org.

Contact
Tom Halkin
National Brain Tumor Society
***@braintumor.org


Source: National Brain Tumor Society

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
  • New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
  • BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
  • Orim Link Inc. Announces Official Launch, Bringing Modern Business Technology Solutions to Charlotte
  • FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
  • Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
  • "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
  • Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
  • Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
  • LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
  • Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
  • High Rise: Path to Nowhere (2022) — A High-Stakes Thriller Filmed in Charlotte, North Carolina
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • 15,000+ Fans Expected at the 2026 BIG HBCU Southern Classic Battle of the Bands in Charlotte
_catLbl0 _catLbl1

Popular on ncarol.com

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 488
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • Wise Business Plans Launches Tailored Business Plan Writing Services for North Carolina Entrepreneur
  • Schemawriter.ai launches WordPress plugin as industry leaders confirm - schema markup is critical
  • Webinar Announcement: Reputational Risk Management in Internal Investigations: Controlling the Narrative Before, During, and After a Crisis
  • Putting Your Roses to Bed for Winter in the Deep South - A Gentleman's Guide to Fall Rose Care
  • Dental Care Solutions Unveils New Website for Enhanced Patient Engagement
  • TradingHabits.com Launches to Support Day Trader Well-being
  • Vet Maps Launches National Platform to Spotlight Veteran-Owned Businesses and Causes
  • $114.6 Million in Revenues, Up 54%: Uni-Fuels Holdings (N A S D A Q: UFG) Accelerates Global Expansion Across Major Shipping Hubs as Demand Surges

Similar on ncarol.com

  • Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • "Latino Leaders Speak: Personal Stories of Struggle and Triumph, Volume II" Documents the Truth About Latino Excellence and Impact on American Society
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute